Full Press Release Details
BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing.
BBIO
BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing
Key Takeaway: BridgeBio Pharma Licenses Late-stage Oncology Drug Infigratinib To Tackle FGFR-driven Maladies; Establishes New Subsidiary QED Therapeutics With $65 Million In Initial Financing
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis